Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Albendazole
Treatment for Ascariasis
Typical Dosage: 400 mg oral single dose
Effectiveness
95%
Safety Score
70%
Clinical Trials
8
Participants
2M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg oral single dose
Time to Effect
1-3 days
Treatment Duration
Single dose
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10
Monitoring:$600
Side Effect Mgmt:$0
Total Annual:$610
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$10.2
Cost per Remission
$10.53
Prescription Access Economics
Annual Societal Loss per Patient
$110
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$35/year
Travel + wait time
Insurance Admin Cost
$20/year
Prior auth, claims
Rx Price
$10/year
Potential OTC Price
$5/year
Estimated if OTC available
Early Treatment Benefit
+0.01 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWAlbendazole Outcomes
for Ascariasis
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+98%
Remission Rate
+95%
Common Side Effects
Abdominal pain
+10%
Nausea/Vomiting
+8%
Headache
+5%
Dizziness
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
7 completed trials for Albendazole in Ascariasis
Efficacy Albendazole and Levamisole Against STH on Unguja
NCT00659997COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Stone Town, Tanzania
Started: Jun 1, 2006
Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
NCT06188715COMPLETEDPHASE3
224 participants
INTERVENTIONAL
Chake Chake, Tanzania
Started: May 14, 2024
Efficacy and Safety of MOX/ALB Co-administration
NCT04726969COMPLETEDPHASE3
255 participants
INTERVENTIONAL
Abidjan, Côte d’Ivoire
Started: Jun 15, 2021
Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children
NCT01658774COMPLETEDNA
2.38K participants
INTERVENTIONAL
Nairobi, Kenya
Started: Jan 1, 2013
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
NCT00207753COMPLETEDNA
550 participants
INTERVENTIONAL
Poptún, Guatemala
Started: Feb 1, 2005
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
NCT06184399COMPLETEDPHASE2
260 participants
INTERVENTIONAL
Chake Chake, Tanzania
Started: Jun 5, 2024
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
NCT04700423COMPLETEDPHASE2, PHASE3
536 participants
INTERVENTIONAL
Chake Chake, Tanzania
Started: Mar 1, 2021